{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:58:31Z","timestamp":1790873911610,"version":"4.1.0"},"reference-count":37,"publisher":"Wiley","issue":"16","license":[{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and aims<\/jats:title><jats:p>Hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) predicts a poor prognosis. The aim of the present study was to evaluate the efficacy and safety of using lenvatinib and camrelizumab combined with transarterial chemoembolization (TACE) to treat HCC with PVTT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a single\u2010arm, open\u2010label, multicenter, and prospective study. Eligible patients with advanced HCC accompanied by PVTT were enrolled to receive TACE combined with lenvatinib and camrelizumab. The primary endpoint was progression\u2010free survival (PFS), while the secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Between April 2020 and April 2022, 69 patients were successfully enrolled. With a median follow\u2010up time of 17.3\u2009months, the median age of the patient cohort was 57\u2009years (range: 49\u201364\u2009years). According to modified Response Evaluation Criteria in Solid Tumors, the ORR was 26.1% (18 partial responses [PRs]) and the DCR was 78.3% (18 PRs, 36 stable diseases [SDs]). The median PFS (mPFS) and median OS (mOS) were 9.3 and 18.2\u2009months, respectively. And tumor number &gt;3 was identified as an adverse risk factor for both PFS and OS. The most common adverse events across all grades included fatigue (50.7%), hypertension (46.4%), and diarrhea (43.5%). Twenty\u2010four patients (34.8%) experienced Grade 3 toxicity that was relieved by dose adjustment and symptomatic treatment. No treatment\u2010related deaths occurred.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>TACE combined with lenvatinib and camrelizumab is a well\u2010tolerated modality treatment with promising efficacy for advanced HCC with PVTT.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.6302","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T13:32:06Z","timestamp":1688131926000},"page":"16805-16814","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["A multicenter prospective study of <scp>TACE<\/scp> combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus"],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6386-6640","authenticated-orcid":false,"given":"Xiaomi","family":"Li","sequence":"first","affiliation":[{"name":"Department of Cancer Center, Beijing Ditan Hospital Capital Medical University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, Beijing Ditan Hospital Capital Medical University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Beijing You'an Hospital Capital Medical University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, The Fifth Medical Center Chinese PLA General Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, Beijing Ditan Hospital Capital Medical University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Teng","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, Beijing Ditan Hospital Capital Medical University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, Beijing Ditan Hospital Capital Medical University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxiao","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, Beijing Ditan Hospital Capital Medical University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, Beijing Ditan Hospital Capital Medical University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, The Fifth Medical Center Chinese PLA General Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinglong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, Beijing Ditan Hospital Capital Medical University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,6,30]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1713263"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2015.05.009"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199808000-00014"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0022"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.014"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50047"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.33156"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(02)08649-x"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2019.03.042"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(02)08649-x"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(08)70285-7"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.14131946"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)30207-1"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33677"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.821599"},{"key":"e_1_2_11_18_1","first-page":"6107","article-title":"Advanced hepatocellular carcinoma treated by transcatheter arterial chemoembolization with drug\u2010eluting beads plus lenvatinib versus sorafenib, a propensity score matching retrospective study","volume":"11","author":"Xue M","year":"2021","journal-title":"Am J Cancer Res"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.00808"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.S304820"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.694409"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003311"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.835889"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.709060"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00534-010-0314-0"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2015.21.2.115"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2014.10.019"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.03.019"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5847"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051116"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2008.06.017"},{"key":"e_1_2_11_33_1","first-page":"220","article-title":"Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma","volume":"4","author":"Yao DF","year":"2005","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2012.05.004"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt.15.126"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20140559"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12069"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14193"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.6302","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T09:46:52Z","timestamp":1711532812000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.6302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,30]]},"references-count":37,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1002\/cam4.6302"],"URL":"https:\/\/doi.org\/10.1002\/cam4.6302","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,30]]},"assertion":[{"value":"2022-08-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}